Log in to your Inderes Free account to see all free content on this page.
Corline Biomedical
16.05 SEK
-0.62 %
Less than 1K followers
CLBIO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-0.62 %
-1.83 %
-8.55 %
-2.13 %
-20.54 %
+47.25 %
+52.86 %
+52.13 %
+62.26 %
Corline Biomedical is active in the pharmaceutical industry. The company works with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The company sells its proprietary product CHS™ to medical technology customers, and is developing Renaparin® for use in regenerative medicine and organ transplantation. The headquarters are located in Uppsala.
Read moreMarket cap
419.44M SEK
Turnover
147.99K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
8.5.
2026
Interim report Q1'26
12.5.
2026
General meeting '26
26.8.
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Redeye: Corline Biomedical Q3 (Review) - Sales growth incoming
Redeye: Corline Biomedical - Kardium receives FDA approval
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio